#Germany #Düsseldorf #LenioBio #AffinityAI #Designerbodies

Collaboration to Accelerate Protein Discovery

In a groundbreaking development within the biotechnology sector, LenioBio GmbH announced a strategic alliance with AffinityAI, a pioneering Danish start-up specializing in artificial intelligence-driven protein design. This partnership aims to transform the protein discovery landscape by integrating LenioBio's innovative cell-free protein expression platform, ALiCE®, with AffinityAI's cutting-edge design technology, Designerbodies™.

Advancing Protein Design Through Innovation

The partnership represents a significant step forward in the quest to optimize and discover novel proteins more efficiently. Traditionally, the process of protein design and testing has been time-consuming, often stretching over weeks. However, this collaboration introduces a system that expedites these cycles significantly. By merging AI-guided design methodologies with high-throughput cell-free expression, the time needed to move from design to iterative testing and feedback can now be reduced to mere days.

André Goerke, the CEO of LenioBio, highlighted the transformative potential of this integration: “We have reinvented cell-free protein expression to fully harness the power of AI-driven protein design. ALiCE® combines the openness and flexibility of a cell-free system with the scalability of cell-based platforms. Together with AffinityAI, we can speed up discovery cycles and rapidly advance precision-designed protein therapeutics into development.”

The Power of Designerbodies™

AffinityAI's Designerbodies™ are synthetically engineered proteins designed to exhibit high affinity and stable binding capabilities, set apart from conventional antibodies. Their tailored binding sites provide unparalleled precision in targeting specific epitopes on proteins, enhancing their utility across various fields including drug development and diagnostics. Through this partnership, these Designerbodies™ will be subjected to rapid screening and optimization processes facilitated by LenioBio’s ALiCE® platform, creating a pioneering automated pipeline for next-generation protein products.

Dr. Timothy P. Jenkins, Head of Data Science at AffinityAI, noted the synergy between the two companies: “LenioBio's ALiCE® system perfectly enhances our AI-based approach. Together, we can deliver Designerbodies™ faster, at higher throughput, and with unmatched precision.”

Implications for the Biotechnology Industry

This strategic collaboration aligns perfectly with the increased demand for novel protein therapeutics, especially in the current biopharmaceutical landscape where rapid responses and tailored therapies are more crucial than ever. By employing advanced AI techniques for protein design and optimizing the production processes through a scalable, cell-free platform, both LenioBio and AffinityAI are positioned to lead in the competitive biotechnology arena.

The confluence of AI and synthetic biology presents vast opportunities for innovative solutions in medicinal research, diagnostics, and beyond. As these technologies continue to evolve, the implications for patient care and therapeutic development appear promising.

In conclusion, as LenioBio and AffinityAI embark on this promising partnership, the biotechnology community watches closely, anticipating breakthroughs that could redefine the capabilities of protein discovery and therapeutic design. Learn more about LenioBio at leniobio.com and AffinityAI at affinityai.dk.